Search Results

There are 7874 results for: content related to: Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer

  1. Topotecan for ovarian cancer

    Intervention Review

    The Cochrane Library

    Peng Lihua, Xiao Y Chen and Taixiang Wu

    Published Online : 23 APR 2008, DOI: 10.1002/14651858.CD005589.pub2

  2. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity

    Journal of Pharmacy and Pharmacology

    Volume 64, Issue 3, March 2012, Pages: 372–382, Chunlei Li, Caixia Wang, Hanyu Yang, Xi Zhao, Na Wei and Jingxia Cui

    Version of Record online : 16 DEC 2011, DOI: 10.1111/j.2042-7158.2011.01422.x

  3. Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function

    British Journal of Clinical Pharmacology

    Volume 80, Issue 2, August 2015, Pages: 253–266, Lot A. Devriese, Petronella (Els). O. Witteveen, Marja Mergui-Roelvink, Deborah A. Smith, Lionel D. Lewis, David S. Mendelson, Yung-Jue Bang, Hyun Choel Chung, Mohammed M. Dar, Alwin D. R. Huitema, Jos H. Beijnen, Emile E. Voest and Jan H. M. Schellens

    Version of Record online : 20 MAY 2015, DOI: 10.1111/bcp.12606

  4. Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy

    International Journal of Gynecological Cancer

    Volume 17, Issue 3, May/June 2007, Pages: 589–594, P. SABBATINI, D. MOONEY, A. IASONOS, H. THALER, C. AGHAJANIAN, M. HENSLEY, J. KONNER, D. SPRIGGS, N.R. ABU-RUSTUM and J. DUPONT

    Version of Record online : 9 FEB 2007, DOI: 10.1111/j.1525-1438.2007.00823.x

  5. You have free access to this content
    Subunit-dependent inhibition and potentiation of 5-HT3 receptor by the anticancer drug, topotecan

    Journal of Neurochemistry

    Volume 125, Issue 1, April 2013, Pages: 7–15, Yukiko Nakamura, Yusuke Ishida, Takahiro Yamada, Makoto Kondo and Shoichi Shimada

    Version of Record online : 31 JAN 2013, DOI: 10.1111/jnc.12146

  6. A Phase I Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Topotecan at 4 mg/m2 Administered Weekly as a 30-Minute Intravenous Infusion in Patients With Cancer

    The Journal of Clinical Pharmacology

    Volume 50, Issue 3, March 2010, Pages: 268–275, Dr Kelly K. Curtis, Ms Jean T. Hartney, Dr Roxanne C. Jewell, Dr Jung W. Park, Dr Peter F. Lebowitz, Ms Pamela P. Griffin, Dr Mitesh J. Borad, Dr Tom R. Fitch and Dr Donald W. Northfelt

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009343699

  7. Randomized single-agents trials in recurrent epithelial ovarian cancer

    International Journal of Gynecological Cancer

    Volume 15, Issue s3, November 2005, Pages: 247–251, C. SESSA and S. MARSONI

    Version of Record online : 18 NOV 2005, DOI: 10.1111/j.1525-1438.2005.00437.x

  8. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: A single institutional experience

    Journal of Obstetrics and Gynaecology Research

    Volume 36, Issue 1, February 2010, Pages: 86–93, Hee Seung Kim, Noh Hyun Park, Sokbom Kang, Sang-Soo Seo, Hyun Hoon Chung, Jae Weon Kim, Yong Sang Song and Soon-Beom Kang

    Version of Record online : 4 FEB 2010, DOI: 10.1111/j.1447-0756.2009.01101.x

  9. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice

    European Journal of Clinical Investigation

    Volume 36, Issue 6, June 2006, Pages: 409–418, X. Li, W. L. Lu, G. W. Liang, G. R. Ruan, H. Y. Hong, C. Long, Y. T. Zhang, Y. Liu, J. C. Wang, X. Zhang and Q. Zhang

    Version of Record online : 8 MAY 2006, DOI: 10.1111/j.1365-2362.2006.01643.x

  10. Topotecan in cervical cancer

    International Journal of Gynecological Cancer

    Volume 17, Issue 6, November/December 2007, Pages: 1215–1223, S. ACKERMANN, M. W. BECKMANN, F. THIEL and T. BOGENRIEDER

    Version of Record online : 20 JUL 2007, DOI: 10.1111/j.1525-1438.2007.01003.x

  11. You have free access to this content
    A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy

    International Journal of Gynecological Cancer

    Volume 18, Issue 1, January/February 2008, Pages: 51–58, A.H. COMANDER and S.A. CANNISTRA

    Version of Record online : 15 MAY 2007, DOI: 10.1111/j.1525-1438.2007.00978.x

  12. Treatment of relapsed Wilms tumour (WT) patients: Experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG)

    Pediatric Blood & Cancer

    Volume 62, Issue 4, April 2015, Pages: 598–602, A. M. C. Mavinkurve-Groothuis, M. M. van den Heuvel-Eibrink, G. A. Tytgat, H. van Tinteren, G. Vujanic, K. L. P. Pritchard-Jones, L. Howell, N. Graf, C. Bergeron, T. Acha, S. Catania and F. Spreafico

    Version of Record online : 29 DEC 2014, DOI: 10.1002/pbc.25357

  13. Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma

    International Journal of Gynecological Cancer

    Volume 15, Issue 4, July 2005, Pages: 612–617, B. PIURA and A. RABINOVICH

    Version of Record online : 7 JUL 2005, DOI: 10.1111/j.1525-1438.2005.00116.x

  14. Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer

    International Journal of Gynecological Cancer

    Volume 17, Issue 1, January/February 2007, Pages: 83–87, I. VANDENPUT, F. AMANT, P. NEVEN, P. BERTELOOT, K. LEUNEN and I. VERGOTE

    Version of Record online : 11 JAN 2007, DOI: 10.1111/j.1525-1438.2007.00789.x

  15. You have free access to this content
    Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma

    Cancer

    Volume 95, Issue 8, 15 October 2002, Pages: 1656–1662, Bo Gronlund, Heine H. Hansen, Claus Høgdall and Svend A. Engelholm

    Version of Record online : 3 OCT 2002, DOI: 10.1002/cncr.10838

  16. You have free access to this content
    A Phase I–II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent müllerian tumors

    Cancer

    Volume 92, Issue 5, 1 September 2001, Pages: 1156–1167, Richard T. Penson, Jeffrey G. Supko, Michael V. Seiden, Arlan F. Fuller, Ross S. Berkowitz, Annekathryn Goodman, Susana M. Campos, Kimberley M. MacNeill, Sarah Cook and Ursula A. Matulonis

    Version of Record online : 18 SEP 2001, DOI: 10.1002/1097-0142(20010901)92:5<1156::AID-CNCR1434>3.0.CO;2-G

  17. You have free access to this content
    Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway

    International Journal of Cancer

    Volume 98, Issue 1, 1 March 2002, Pages: 36–41, Ayako Nakashio, Naoya Fujita and Takashi Tsuruo

    Version of Record online : 18 DEC 2001, DOI: 10.1002/ijc.10166

  18. Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer

    British Journal of Pharmacology

    Volume 172, Issue 16, August 2015, Pages: 4089–4106, Kenneth K W To, Daniel C Poon, Yuming Wei, Fang Wang, Ge Lin and Liwu Fu

    Version of Record online : 26 JUN 2015, DOI: 10.1111/bph.13189

  19. You have free access to this content
    Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic

    International Journal of Cancer

    Volume 108, Issue 1, 1 January 2004, Pages: 146–151, Ken Shiozawa, Mikio Oka, Hiroshi Soda, Megumi Yoshikawa, Yoji Ikegami, Junji Tsurutani, Katsumi Nakatomi, Yoichi Nakamura, Seiji Doi, Takeshi Kitazaki, Yohei Mizuta, Kunihiko Murase, Hisahiro Yoshida, Douglas D. Ross and Shigeru Kohno

    Version of Record online : 24 SEP 2003, DOI: 10.1002/ijc.11528

  20. A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer

    International Journal of Gynecological Cancer

    Volume 17, Issue 2, March/April 2007, Pages: 367–372, F. VECCHIONE, R. FRUSCIO, T. DELL’ANNA, A. GARBI, R. GARCIA PARRA, S. CORSO and A.A. LISSONI

    Version of Record online : 11 JAN 2007, DOI: 10.1111/j.1525-1438.2007.00797.x